Wei Peng, Romanò Cecilia, Li Chengxin, Clergeaud Gael, Andresen Thomas L, Henriksen Jonas R, Hansen Anders E, Clausen Mads H
Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Kongens Lyngby, 2800, Denmark.
Department of Chemistry, Technical University of Denmark, Kongens Lyngby, 2800, Denmark.
Commun Biol. 2024 Sep 17;7(1):1158. doi: 10.1038/s42003-024-06806-1.
Diseases caused by S. pneumoniae are the leading cause of child mortality. As antibiotic resistance of S. pneumoniae is rising, vaccination remains the most recommended solution. However, the existing pneumococcal polysaccharides vaccine (Pneumovax 23) proved only to induce T-independent immunity, and strict cold chain dependence of the protein conjugate vaccine impedes its promotion in developing countries, where infections are most problematic. Affordable and efficient vaccines against pneumococcus are therefore in high demand. Here, we present an intranasal vaccine LipoCPS12F&αGC, containing the capsular polysaccharides of S. pneumoniae 12F and the iNKT agonist α-galactosylceramide in cationic liposomes. In BALB/cJRj mice, the vaccine effectively activates iNKT cells and promotes B cells maturation, stimulates affinity-matured IgA and IgG production in both the respiratory tract and systemic blood, and displays sufficient protection both in vivo and in vitro. The designed vaccine is a promising, cost-effective solution against pneumococcus, which can be expanded to cover more serotypes and pathogens.
肺炎链球菌引起的疾病是儿童死亡的主要原因。随着肺炎链球菌抗生素耐药性的上升，接种疫苗仍然是最推荐的解决方案。然而，现有的肺炎球菌多糖疫苗（Pneumovax 23）仅被证明能诱导非T细胞依赖性免疫，而蛋白结合疫苗对冷链的严格依赖阻碍了其在感染问题最为严重的发展中国家的推广。因此，对价格合理且高效的肺炎球菌疫苗需求很高。在此，我们展示了一种鼻内疫苗LipoCPS12F&αGC，其在阳离子脂质体中含有肺炎链球菌12F的荚膜多糖和iNKT激动剂α-半乳糖神经酰胺。在BALB/cJRj小鼠中，该疫苗能有效激活iNKT细胞并促进B细胞成熟，刺激呼吸道和全身血液中亲和力成熟的IgA和IgG产生，且在体内和体外均显示出足够的保护作用。所设计的疫苗是一种有前景的、具有成本效益的抗肺炎球菌解决方案，可扩展以覆盖更多血清型和病原体。
